ER+/HER2- ADVANCED OR METASTATIC BREAST CANCER
Clinical trials for ER+/HER2- ADVANCED OR METASTATIC BREAST CANCER explained in plain language.
Never miss a new study
Get alerted when new ER+/HER2- ADVANCED OR METASTATIC BREAST CANCER trials appear
Sign up with your email to follow new studies for ER+/HER2- ADVANCED OR METASTATIC BREAST CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug combo shows promise for Tough-to-Treat breast cancer
Disease control OngoingThis study tests two oral medications, vepdegestrant and samuraciclib, taken daily at home by adults with advanced or metastatic ER+ breast cancer that no longer responds to standard treatments. The goal is to see if the combination is safe and can shrink or control the cancer. P…
Matched conditions: ER+/HER2- ADVANCED OR METASTATIC BREAST CANCER
Phase: PHASE1, PHASE2 • Sponsor: Pfizer • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New drug combo aims to control advanced breast cancer
Disease control OngoingThis study tests a new oral drug, ARV-471, combined with ribociclib in adults with advanced or metastatic ER+ breast cancer that has stopped responding to previous treatments. The goal is to see if the combination is safe and can shrink tumors or slow cancer growth. Participants …
Matched conditions: ER+/HER2- ADVANCED OR METASTATIC BREAST CANCER
Phase: PHASE1, PHASE2 • Sponsor: Pfizer • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
New pill combo shows promise for Tough-to-Treat breast cancer
Disease control OngoingThis study tests two oral drugs, vepdegestrant and PF-07220060, in people with advanced or metastatic ER+/HER2- breast cancer that has stopped responding to prior treatments. The goal is to see if the combination is safe and can shrink tumors. Participants take the pills at home …
Matched conditions: ER+/HER2- ADVANCED OR METASTATIC BREAST CANCER
Phase: PHASE1, PHASE2 • Sponsor: Pfizer • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC